ASCO 2022 Conference Coverage
Playback speed
10 seconds
Lecture Summary - ASCO 2022 Subgroup Analysis of Patients With No Prior Chemo in Phase 3 EMERALD Trial: Elacestrant vs. Investigator’s Choice of Endocrine Monotherapy for ER+/HER2 mBC
By
ASCO 2022 Conference Coverage
FEATURING
Virginia Kaklamani
By
ASCO 2022 Conference Coverage
FEATURING
Virginia Kaklamani
49 views
June 10, 2022
Login to view comments.
Click here to Login
Breast